Celldex Therapeutics (CLDX) Share-based Compensation (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Share-based Compensation of $8.5 million for Q1 2026, down 8.51% year-over-year from $9.3 million in Q1 2025, and down 4.33% quarter-over-quarter from $8.9 million in Q4 2025.
Celldex Therapeutics (CLDX) Share-based Compensation (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 8.51% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $35.9 million (down 1.15% YoY), while the FY2025 annual figure was $65.3 million, down 15.3% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.5 million, down from $8.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $72.8 million in Q3 2025, with the low at $3.2 million in Q1 2022.
- The 5-year median for Share-based Compensation is $7.2 million (2023), against an average of $10.7 million.
- Peak annual rise in Share-based Compensation reached 656.76% in 2025, while the deepest fall reached 8.91% in 2025.
- Celldex Therapeutics' Share-based Compensation stood at $4.5 million in 2022, then surged by 59.98% to $7.2 million in 2023, then surged by 35.61% to $9.8 million in 2024, then retreated by 8.91% to $8.9 million in 2025, then decreased by 4.33% to $8.5 million in 2026.
- Business Quant data shows CLDX's Share-based Compensation at $8.5 million in Q1 2026, $8.9 million in Q4 2025, and $72.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 8.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.41 Mn |
| Jun 30, 2026 | 8.41 Mn |
| Mar 31, 2026 | 8.52 Mn |
| Mar 31, 2026 | 8.52 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Sep 30, 2025 | 72.80 Mn |
| Sep 30, 2025 | 72.80 Mn |
| Jun 30, 2025 | 9.19 Mn |
| Jun 30, 2025 | 9.19 Mn |
| Mar 31, 2025 | 9.32 Mn |
| Mar 31, 2025 | 9.32 Mn |
| Dec 31, 2024 | 9.78 Mn |
| Dec 31, 2024 | 9.78 Mn |
| Sep 30, 2024 | 9.62 Mn |
| Sep 30, 2024 | 9.62 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Mar 31, 2024 | 7.20 Mn |
| Mar 31, 2024 | 7.20 Mn |